Nama's AI scorecard currently rates Medpace Buy (7.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is MEDP's P/E ratio?

Medpace trades at a trailing price-to-earnings ratio of 36.2.

When does MEDP report earnings?

Medpace's next scheduled report is on Feb 8, 2027. Analysts expect EPS of $4.88.

What is the MEDP price target?

The median analyst price target from 13 analysts is $675.00, with a range of $370.00 – $730.00.

Is MEDP Shariah compliant?

Nama's AAOIFI-style screen reads Medpace as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Medpace (MEDP)

Healthcare · Diagnostics Research · NASDAQ

Medpace (MEDP) is a Healthcare company in the Diagnostics Research industry. It has a market capitalization of $18.27B, a trailing price-to-earnings ratio of 36.2 and a free-cash-flow yield of 3.5%. Over the most recent reported fiscal year, revenue grew 20.0% and free cash flow per share grew 29.2%. Nama's AI scorecard rates it Buy, 7.1 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Buy · 7.1/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Middle · +2.0% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-5.9%

How far the last close sits under the highest price of the past five years.

Market cap	$18.27B
Trailing P/E	36.2
Price / book	31.2
Price / sales	6.4
FCF yield	3.5%
Dividend yield	—
Gross margin	29.1%
Operating margin	21.4%
Net margin	18.2%
Revenue growth (YoY)	+20.0%
Revenue growth (3-yr annual)	+20.1%
EPS growth (YoY)	+20.8%
FCF/share growth (YoY)	+29.2%
Beta	1.2
Exchange	NASDAQ
Sector	Healthcare
Industry	Diagnostics Research

MEDP earnings

Next report: Feb 8, 2027 (Q4 2026, EPS estimate $4.88). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 21, 2026	$4.84	$4.46	+8.5%	$716.00M
Q2 2026	Jul 22, 2026	$4.25	$4.00	+6.2%	$707.33M
Q1 2026	Apr 22, 2026	$4.28	$3.96	+8.1%	$706.60M
Q4 2025	Feb 9, 2026	$4.67	$4.23	+10.4%	$708.45M

MEDP analyst price target

Median target $675.00 from 13 analysts, ranging $370.00 – $730.00.

Diagnostics Research peers

Ticker	Company	Market cap	P/E
TMO	Thermo Fisher Scientific	$257.42B	28.1
DHR	Danaher	$161.86B	27.6
IDXX	IDEXX Laboratories	$53.26B	45.6
A	Agilent Technologies	$49.28B	28.8
WAT	Waters	$44.93B	31.8
IQV	IQVIA	$44.80B	21.2
NTRA	Natera	$44.78B	—
MTD	Mettler-Toledo International	$34.51B	37.2

Explore live MEDP data on Nama Insights →

Recent Congressional trades

Medpace trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
David J. Taylor	House	Buy	$1,001 - $15,000	May 28, 2026
David J. Taylor	House	Buy	$1,001 - $15,000	Mar 6, 2026
Gilbert Cisneros	House	Sell	$15,001 - $50,000	Feb 13, 2026
David J. Taylor	House	Buy	$1,001 - $15,000	Feb 2, 2026
David J. Taylor	House	Sell	$1,001 - $15,000	Feb 2, 2026
Gilbert Cisneros	House	Sell	$1,001 - $15,000	Nov 18, 2025
Lisa McClain	House	Sell	$1,001 - $15,000	Sep 12, 2025
David J. Taylor	House	Sell	$1,001 - $15,000	Sep 2, 2025
Gilbert Cisneros	House	Sell	$1,001 - $15,000	Aug 14, 2025
Lisa McClain	House	Buy	$1,001 - $15,000	Aug 13, 2025
Rob Bresnahan	House	Sell	$1,001 - $15,000	Feb 13, 2025
Josh Gottheimer	House	Sell	$1,001 - $15,000	Aug 15, 2024

MEDP FAQ

Is MEDP a buy?: Nama's AI scorecard currently rates Medpace Buy (7.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is MEDP's P/E ratio?: Medpace trades at a trailing price-to-earnings ratio of 36.2.
When does MEDP report earnings?: Medpace's next scheduled report is on Feb 8, 2027. Analysts expect EPS of $4.88.
What is the MEDP price target?: The median analyst price target from 13 analysts is $675.00, with a range of $370.00 – $730.00.
Is MEDP Shariah compliant?: Nama's AAOIFI-style screen reads Medpace as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.